Global Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

According to APO Research, The global Migraine Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Migraine Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Migraine Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Migraine Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Migraine Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Migraine Drugs include Abbott, Johnson & Johnson, Merck, Eli Lilly, Pfizer, Pfizer, Bayer, Winston Pharmaceuticals and Teva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Migraine Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Migraine Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Migraine Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Migraine Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Migraine Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Migraine Drugs sales, projected growth trends, production technology, application and end-user industry.


Migraine Drugs Segment by Company

Abbott
Johnson & Johnson
Merck
Eli Lilly
Pfizer
Pfizer
Bayer
Winston Pharmaceuticals
Teva
Kowa Pharmaceuticals America
Impax
GlaxoSmithKline
Ethypharm
Endo International
AstraZeneca
Allergan

Migraine Drugs Segment by Type

Rizatriptan
Others Drug
Sumatriptan
Zolmitriptan

Migraine Drugs Segment by Application

Hospitals
Clinics
Household Use
Others

Migraine Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Migraine Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Migraine Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Migraine Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Migraine Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Migraine Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Migraine Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Migraine Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Migraine Drugs Market Dynamics
2.1 Migraine Drugs Industry Trends
2.2 Migraine Drugs Industry Drivers
2.3 Migraine Drugs Industry Opportunities and Challenges
2.4 Migraine Drugs Industry Restraints
3 Migraine Drugs Market by Manufacturers
3.1 Global Migraine Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Migraine Drugs Sales by Manufacturers (2020-2025)
3.3 Global Migraine Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Migraine Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Migraine Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Migraine Drugs Manufacturers, Product Type & Application
3.7 Global Migraine Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Migraine Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Migraine Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Migraine Drugs Tier 1, Tier 2, and Tier 3
4 Migraine Drugs Market by Type
4.1 Migraine Drugs Type Introduction
4.1.1 Rizatriptan
4.1.2 Others Drug
4.1.3 Sumatriptan
4.1.4 Zolmitriptan
4.2 Global Migraine Drugs Sales by Type
4.2.1 Global Migraine Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Migraine Drugs Sales by Type (2020-2031)
4.2.3 Global Migraine Drugs Sales Market Share by Type (2020-2031)
4.3 Global Migraine Drugs Revenue by Type
4.3.1 Global Migraine Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Migraine Drugs Revenue by Type (2020-2031)
4.3.3 Global Migraine Drugs Revenue Market Share by Type (2020-2031)
5 Migraine Drugs Market by Application
5.1 Migraine Drugs Application Introduction
5.1.1 Hospitals
5.1.2 Clinics
5.1.3 Household Use
5.1.4 Others
5.2 Global Migraine Drugs Sales by Application
5.2.1 Global Migraine Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Migraine Drugs Sales by Application (2020-2031)
5.2.3 Global Migraine Drugs Sales Market Share by Application (2020-2031)
5.3 Global Migraine Drugs Revenue by Application
5.3.1 Global Migraine Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Migraine Drugs Revenue by Application (2020-2031)
5.3.3 Global Migraine Drugs Revenue Market Share by Application (2020-2031)
6 Global Migraine Drugs Sales by Region
6.1 Global Migraine Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Migraine Drugs Sales by Region (2020-2031)
6.2.1 Global Migraine Drugs Sales by Region (2020-2025)
6.2.2 Global Migraine Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Migraine Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Migraine Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Migraine Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Migraine Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Migraine Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Migraine Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Migraine Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Migraine Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Migraine Drugs Revenue by Region
7.1 Global Migraine Drugs Revenue by Region
7.1.1 Global Migraine Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Migraine Drugs Revenue by Region (2020-2025)
7.1.3 Global Migraine Drugs Revenue by Region (2026-2031)
7.1.4 Global Migraine Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Migraine Drugs Revenue (2020-2031)
7.2.2 North America Migraine Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Migraine Drugs Revenue (2020-2031)
7.3.2 Europe Migraine Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Migraine Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Migraine Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Migraine Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Migraine Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Abbott
8.1.1 Abbott Comapny Information
8.1.2 Abbott Business Overview
8.1.3 Abbott Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Abbott Migraine Drugs Product Portfolio
8.1.5 Abbott Recent Developments
8.2 Johnson & Johnson
8.2.1 Johnson & Johnson Comapny Information
8.2.2 Johnson & Johnson Business Overview
8.2.3 Johnson & Johnson Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Johnson & Johnson Migraine Drugs Product Portfolio
8.2.5 Johnson & Johnson Recent Developments
8.3 Merck
8.3.1 Merck Comapny Information
8.3.2 Merck Business Overview
8.3.3 Merck Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Merck Migraine Drugs Product Portfolio
8.3.5 Merck Recent Developments
8.4 Eli Lilly
8.4.1 Eli Lilly Comapny Information
8.4.2 Eli Lilly Business Overview
8.4.3 Eli Lilly Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Eli Lilly Migraine Drugs Product Portfolio
8.4.5 Eli Lilly Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pfizer Migraine Drugs Product Portfolio
8.5.5 Pfizer Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Pfizer Migraine Drugs Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Bayer
8.7.1 Bayer Comapny Information
8.7.2 Bayer Business Overview
8.7.3 Bayer Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Bayer Migraine Drugs Product Portfolio
8.7.5 Bayer Recent Developments
8.8 Winston Pharmaceuticals
8.8.1 Winston Pharmaceuticals Comapny Information
8.8.2 Winston Pharmaceuticals Business Overview
8.8.3 Winston Pharmaceuticals Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Winston Pharmaceuticals Migraine Drugs Product Portfolio
8.8.5 Winston Pharmaceuticals Recent Developments
8.9 Teva
8.9.1 Teva Comapny Information
8.9.2 Teva Business Overview
8.9.3 Teva Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Teva Migraine Drugs Product Portfolio
8.9.5 Teva Recent Developments
8.10 Kowa Pharmaceuticals America
8.10.1 Kowa Pharmaceuticals America Comapny Information
8.10.2 Kowa Pharmaceuticals America Business Overview
8.10.3 Kowa Pharmaceuticals America Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Kowa Pharmaceuticals America Migraine Drugs Product Portfolio
8.10.5 Kowa Pharmaceuticals America Recent Developments
8.11 Impax
8.11.1 Impax Comapny Information
8.11.2 Impax Business Overview
8.11.3 Impax Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Impax Migraine Drugs Product Portfolio
8.11.5 Impax Recent Developments
8.12 GlaxoSmithKline
8.12.1 GlaxoSmithKline Comapny Information
8.12.2 GlaxoSmithKline Business Overview
8.12.3 GlaxoSmithKline Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 GlaxoSmithKline Migraine Drugs Product Portfolio
8.12.5 GlaxoSmithKline Recent Developments
8.13 Ethypharm
8.13.1 Ethypharm Comapny Information
8.13.2 Ethypharm Business Overview
8.13.3 Ethypharm Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Ethypharm Migraine Drugs Product Portfolio
8.13.5 Ethypharm Recent Developments
8.14 Endo International
8.14.1 Endo International Comapny Information
8.14.2 Endo International Business Overview
8.14.3 Endo International Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Endo International Migraine Drugs Product Portfolio
8.14.5 Endo International Recent Developments
8.15 AstraZeneca
8.15.1 AstraZeneca Comapny Information
8.15.2 AstraZeneca Business Overview
8.15.3 AstraZeneca Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 AstraZeneca Migraine Drugs Product Portfolio
8.15.5 AstraZeneca Recent Developments
8.16 Allergan
8.16.1 Allergan Comapny Information
8.16.2 Allergan Business Overview
8.16.3 Allergan Migraine Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.16.4 Allergan Migraine Drugs Product Portfolio
8.16.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Migraine Drugs Value Chain Analysis
9.1.1 Migraine Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Migraine Drugs Production Mode & Process
9.2 Migraine Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Migraine Drugs Distributors
9.2.3 Migraine Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings